Business Context and Reporting Period
This Form 8-K filing by ReWalk Robotics Ltd. (noted as Lifeward Ltd. in metadata) is dated April 3, 2019. The report details a registered direct offering of ordinary shares and warrants, alongside preliminary financial results for the three months ended March 31, 2019. The company is an emerging growth company incorporated in Israel.
Key Financial Metrics
- Revenue: Approximately $1.5 million to $1.6 million for the three months ended March 31, 2019.
- Cash and Cash Equivalents: Approximately $8.8 million as of March 31, 2019.
- Offering Proceeds: Expected gross proceeds of approximately $4.25 million from the sale of 816,914 ordinary shares at $5.2025 per share.
- Profit, Margins, and Debt: The filing text does not provide clear values for net profit, operating margins, or specific debt balances.
- Liquidity: The company anticipates using net proceeds to fund sales, marketing, reimbursement activities, and R&D for the ReStore exo-suit.
Material Changes and Transactions
The primary material event is the entry into a Purchase Agreement with institutional investors and an Engagement Letter with H.C. Wainwright & Co., LLC as the exclusive placement agent. The company sold 816,914 ordinary shares and issued warrants to purchase up to 408,457 shares at an exercise price of $5.14. Additionally, the company issued warrants to the placement agent to purchase up to 49,015 shares at $6.503125. The offering was expected to close on April 5, 2019.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use proceeds for market development, third-party payor coverage, and R&D for stroke recovery technology. Preliminary financial results are subject to adjustment upon completion of the quarterly review.
Risks and Contingencies:
- Going Concern: Management and auditors have expressed substantial doubt regarding the company's ability to continue as a going concern.
- Listing Compliance: Risks exist regarding compliance with Nasdaq Capital Market listing requirements, potentially requiring a reverse share split.
- Regulatory and Clinical: Risks include FDA regulatory developments, mandatory post-market surveillance studies, and the ability to achieve reimbursement.
- Litigation: Ongoing shareholder class action litigation related to the initial public offering.
- Dilution: Risks of substantial dilution from periodic issuances of ordinary shares.
Investor Verification Checklist
- Verify the final closing of the $4.25 million registered direct offering and the actual net proceeds received.
- Confirm the company's status regarding Nasdaq listing compliance and any executed reverse share splits.
- Review the upcoming unaudited consolidated condensed financial statements for the quarter ended March 31, 2019, to validate the preliminary revenue and cash figures.
- Monitor updates on the "substantial doubt" regarding the company's ability to continue as a going concern.
- Track progress on third-party payor reimbursement and the ReStore exo-suit R&D milestones.